Alkermes (NASDAQ:ALKS) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research initiated coverage on shares of Alkermes (NASDAQ:ALKS) in a report released on Monday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $45.00 target price on the stock.

Other analysts have also issued reports about the stock. Bank of America upped their price target on shares of Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the company a “buy” rating in a research note on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft dropped their price objective on Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Wells Fargo & Company decreased their target price on shares of Alkermes from $42.00 to $37.00 and set an “overweight” rating on the stock in a research note on Thursday, November 13th. Finally, Wall Street Zen cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Alkermes Trading Down 7.0%

ALKS opened at $31.04 on Monday. The stock has a market capitalization of $5.13 billion, a P/E ratio of 15.37 and a beta of 0.49. The stock has a 50-day moving average price of $31.44 and a 200-day moving average price of $30.17. Alkermes has a 12-month low of $25.17 and a 12-month high of $36.32.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to the consensus estimate of $380.44 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business’s quarterly revenue was down 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, equities research analysts predict that Alkermes will post 1.31 EPS for the current year.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president owned 57,740 shares in the company, valued at approximately $1,959,118.20. This represents a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shane Cooke sold 61,200 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the sale, the director directly owned 103,744 shares in the company, valued at $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 148,148 shares of company stock worth $5,028,378 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALKS. Assetmark Inc. boosted its holdings in Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Alkermes in the 4th quarter worth about $28,000. Johnson Financial Group Inc. bought a new position in Alkermes in the 3rd quarter worth about $31,000. UMB Bank n.a. grew its position in Alkermes by 57.6% during the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 446 shares during the last quarter. Finally, Salomon & Ludwin LLC grew its holdings in shares of Alkermes by 115.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after buying an additional 667 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $45 price target, signaling institutional bullishness and significant upside vs. the current level. Wolfe Research Initiation
• Positive Sentiment: Cited coverage from Zacks highlighted Q4 results as topping some estimates (Zacks reported EPS of $0.46 vs. a $0.43 consensus in one story), which some outlets framed as a beat on the quarter. Zacks: Q4 Earnings Top Estimates
• Neutral Sentiment: Management announced a CEO succession plan (current COO Blair Jackson to become CEO Aug. 1, 2026), a governance/leadership change that appears orderly but is likely neutral near term. CEO Succession Plan
• Neutral Sentiment: Alkermes is presenting at industry conferences and recently closed the Avadel acquisition integration is being noted by analysts — these are operational items investors will monitor for cadence and synergy updates. Avadel Acquisition Note
• Neutral Sentiment: Short‑interest data in public feeds showed an anomalous “0 shares / NaN change” print for February — treat those numbers as unreliable until exchanges update official figures. (Data issue flagged by multiple feeds.)
• Negative Sentiment: Management issued very weak FY‑2026 EPS guidance of -0.798 to -0.680 vs. the Street’s prior consensus near +1.63 — this large downward earnings revision is the primary negative driver for the stock today. Q4 Results & FY‑2026 Guidance
• Negative Sentiment: Company‑reported Q4 results were viewed as mixed to weak by some outlets: revenue roughly in line (~$384.6M) but revenue down year‑over‑year and several reports show EPS materially below last year’s levels — reinforcing concerns about near‑term profitability. MarketBeat: Q4 Results & Call

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.